-
Tytuł:
-
Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.
-
Autorzy:
-
Shi D; Peking University People's Hospital, Beijing, China.
Shi H; Peking University People's Hospital, Beijing, China.
Liu X; Nanfang Hospital, Southern Medical University, Guangzhou, China.
Duan M; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhuang J; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Du X; Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Qin L; The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Henan, China.
Hui W; Xuanwu Hospital, Capital Medical University, Beijing, China.
Liang R; Xi Jing Hospital, The Fourth Military Medical University, Shanxi, China.
Wang M; Second Hospital of Shanxi Medical University, Shanxi, China.
Chen Y; Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Li D; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Yang W; Shengjing Hospital Affiliated to China Medical University, Shenyang, China.
Tang G; Changhai Hospital, Second Military Medical University, Shanghai, China.
Zhang W; First Hospital of Shanxi Medical University, Shanxi, China.
Kuang X; Kaifeng Central Hospital, Henan, China.
Su W; Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Han Y; The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Chen L; The First Affiliated Hospital of Xi'an Jiaotong University, Shanxi, China.
Xu J; Qiqihar First Hospital, Heilongjiang, China.
Liu Z; Shengjing Hospital Affiliated to China Medical University, Shenyang, China.
Huang J; The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, China.
Zhao C; The Affiliated Hospital of Qingdao University, Qingdao, China Shandong.
Tong H; The First Affiliated Hospital of College of Medicine, Zhejiang University, Zhejiang, China.
Hu J; Fujian Medical University Union Hospital, Fujian, China.
Chen C; Shandong University Qilu Hospital, Shandong, China.
Chen X; Institute of Hematology & Affiliated Hospital, Medicine School, Northwestern University, Shan'xi, China.
Xiao Z; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Jiang Q; Peking University People's Hospital, Beijing, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
-
Źródło:
-
Leukemia & lymphoma [Leuk Lymphoma] 2021 Nov; Vol. 62 (11), pp. 2703-2715. Date of Electronic Publication: 2021 Jun 08.
-
Typ publikacji:
-
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: [Philadelphia, PA] : Taylor & Francis
Original Publication: Chur ; New York : London, UK : Harwood Academic Publishers ; Distributed by STBS, 1989-
-
MeSH Terms:
-
Myeloproliferative Disorders*/diagnosis
Myeloproliferative Disorders*/drug therapy
Myeloproliferative Disorders*/epidemiology
Polycythemia Vera*/diagnosis
Polycythemia Vera*/drug therapy
Polycythemia Vera*/epidemiology
Cross-Sectional Studies ; Humans ; Patient Reported Outcome Measures ; Quality of Life
-
Contributed Indexing:
-
Keywords: CALR mutation; MPN-10; Myeloproliferative neoplasm; patient-reported outcome; ruxolitinib
-
Entry Date(s):
-
Date Created: 20210608 Date Completed: 20211101 Latest Revision: 20211101
-
Update Code:
-
20240104
-
DOI:
-
10.1080/10428194.2021.1933481
-
PMID:
-
34098836
-
We explored variables associated with patient-reported outcomes (PROs) including symptom burden, impact on daily life and work, obstacles during therapy, satisfaction level with therapy, and health-related quality of life in 1500 respondents with myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF) in a multicenter, cross-sectional study across China, a representative of the developing countries. In multivariate analyses, urban household registration and higher education level were significantly-associated with no symptoms at diagnosis in respondents with ET or MF. CALR mutation was significantly-associated with lower MPN-10 scores in respondents with MF. Higher MPN-10 scores were significantly-associated with negative impact on daily life and work as well as lower satisfaction level in respondents with ET, PV and MF. Receiving ruxolitinib was significantly-associated with high satisfaction and satisfaction in respondents with MF. In addition, other demographics and clinical variables were also impacting PROs.
